Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA). It was developed by the Belgian-Dutch...
24 KB (2,250 words) - 06:06, 16 July 2024
to amend certain terms around the development and commercialization of filgotinib. In June 2022, the business announced it would acquire CellPoint for €125...
6 KB (408 words) - 04:22, 18 January 2024
numbers of T-lymphocytes etc. unknown etanercept decoy TNF receptor bDMARD filgotinib Janus kinase (JAK) inhibitor tsDMARD golimumab TNF inhibitor bDMARD gold...
10 KB (869 words) - 17:44, 20 August 2024
and vitiligo. Examples are tofacitinib, baricitinib, upadacitinib and filgotinib. In 2014 researchers discovered that oral JAK inhibitors, when administered...
9 KB (974 words) - 14:46, 22 June 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
31 KB (3,430 words) - 05:24, 28 August 2024
Agency (EMA) recommends that the Janus kinase inhibitors abrocitinib, filgotinib, baricitinib, upadacitinib, and tofacitinib should be used in the following...
36 KB (2,996 words) - 02:16, 28 August 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
9 KB (457 words) - 08:58, 6 August 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
35 KB (3,892 words) - 12:38, 3 August 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
33 KB (2,917 words) - 16:32, 16 July 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
35 KB (3,270 words) - 07:00, 28 August 2024
L04AF01 Tofacitinib L04AF02 Baricitinib L04AF03 Upadacitinib L04AF04 Filgotinib L04AF05 Itacitinib L04AF06 Peficitinib L04AF07 Deucravacitinib L04AF08...
3 KB (367 words) - 15:37, 25 January 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
23 KB (2,087 words) - 09:12, 24 August 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
17 KB (1,672 words) - 11:59, 30 August 2023
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
26 KB (2,102 words) - 02:19, 16 July 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
24 KB (2,932 words) - 03:26, 14 June 2024
payments for Gilead to license the experimental anti-inflammatory drug filgotinib, which may treat rheumatoid arthritis, ulcerative colitis, and Crohn's...
78 KB (7,617 words) - 05:24, 27 August 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
27 KB (3,227 words) - 11:45, 29 July 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
62 KB (6,845 words) - 18:30, 22 August 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
20 KB (2,259 words) - 11:36, 29 July 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
4 KB (443 words) - 07:08, 27 April 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
33 KB (3,686 words) - 07:30, 20 May 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
46 KB (4,534 words) - 22:58, 20 August 2024
T-cell JAK-STAT signaling is inhibited by the medications tofacitinib, filgotinib and upadacitinib which are used in the treatment of ulcerative colitis...
142 KB (16,179 words) - 20:58, 26 July 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
16 KB (1,124 words) - 12:50, 14 January 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
13 KB (1,176 words) - 21:00, 10 July 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
26 KB (2,188 words) - 05:17, 13 June 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
32 KB (2,851 words) - 23:22, 16 August 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
62 KB (7,065 words) - 05:17, 28 June 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
24 KB (1,703 words) - 18:20, 18 August 2024
JAK1 Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod...
43 KB (3,613 words) - 02:13, 16 July 2024